trending Market Intelligence /marketintelligence/en/news-insights/trending/eaPdOTnPm73ic6iOaFy5Zw2 content esgSubNav
In This List

Portola Pharmaceuticals plans $200M common stock offering

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Portola Pharmaceuticals plans $200M common stock offering

Portola Pharmaceuticals Inc. is planning an underwritten public offering of $200 million of its common shares.

Goldman Sachs & Co. LLC, Citigroup, Cowen, and William Blair are acting as joint book-running manager in the offering, with Oppenheimer & Co. Inc. as lead manager. The underwriters will be granted an option to buy up to an additional $30 million common shares in the transaction.

South San Francisco, Calif.-based Portola Pharmaceuticals is developing therapies for serious blood-related disorders.